Host |
Rabbit |
Clone |
SP138 |
Format |
Concentrate |
Method |
P, WB |
Pretreatment |
- |
Positive control |
Skeletal muscle |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide derived from the C-terminus of human desmin protein |
Localization |
Cytoplasm |
Desmin
|
Zytomed Systems GmbH |
SP138 |
1 ml |
Concentrate |
RUO |
504-4384 |
-
|
Host |
Rabbit |
Clone |
ZR240 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Skeletal muscle or rhabdomyosarcoma |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Recombinant human full-length DES protein |
Localization |
Cytoplasm |
Desmin
|
Zeta Corporation |
ZR240 |
1 ml |
Concentrate |
CE/IVD |
Z2536RL |
-
|
Host |
Rabbit |
Clone |
ZR240 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Positive control |
Skeletal muscle or rhabdomyosarcoma |
Dilution |
- |
Isotype |
IgG |
Immunogen |
Recombinant human full-length DES protein |
Localization |
Cytoplasm |
Desmin
|
Zeta Corporation |
ZR240 |
7 ml |
Ready-to-use |
CE/IVD |
Z2536RP |
-
|
Host |
Rabbit |
Clone |
ZR240 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Skeletal muscle or rhabdomyosarcoma |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Recombinant human full-length DES protein |
Localization |
Cytoplasm |
Desmin
|
Zeta Corporation |
ZR240 |
0.5 ml |
Concentrate |
CE/IVD |
Z2536RS |
-
|
Host |
Rabbit |
Clone |
ZR240 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Skeletal muscle or rhabdomyosarcoma |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Recombinant human full-length DES protein |
Localization |
Cytoplasm |
Desmin
|
Zeta Corporation |
ZR240 |
0.1 ml |
Concentrate |
CE/IVD |
Z2536RT |
-
|
Host |
Mouse |
Clone |
BC11 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Lung squamous cell carcinoma |
Dilution |
1:100 - 1:200 |
Isotype |
Mouse IgG1 |
Localization |
Cell membrane |
Desmoglein 3
|
Biocare Medical |
BC11 |
0.1 ml |
Concentrate |
CE/IVD |
CM419A |
-
|
Host |
Mouse |
Clone |
BC11 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Lung squamous cell carcinoma |
Dilution |
1:100 - 1:200 |
Isotype |
Mouse IgG1 |
Localization |
Cell membrane |
Desmoglein 3
|
Biocare Medical |
BC11 |
1 ml |
Concentrate |
CE/IVD |
CM419C |
-
|
Host |
Mouse |
Clone |
BC11 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Lung squamous cell carcinoma |
Dilution |
- |
Isotype |
Mouse IgG1 |
Localization |
Cell membrane |
Desmoglein 3
|
Biocare Medical |
BC11 |
6 ml |
Ready-to-use |
CE/IVD |
PM419AA |
-
|
Host |
Mouse+Rabbit |
Clone |
BC11+polyclonal |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Lung squamous cell carcinoma, lung adenocarcinoma |
Dilution |
- |
Isotype |
Mouse IgG1+not determined |
Localization |
Cell membrane + cytoplasmic |
Desmoglein 3 + Napsin A
|
Biocare Medical |
BC11+polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PPM428DSAA |
-
|
Host |
Mouse+Mouse |
Clone |
BC11+BC28 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Lung squamous cell carcinoma, |
Dilution |
- |
Isotype |
Mouse IgG1 + Mouse IgG1 |
Localization |
Cell membrane + nucleus |
Desmoglein 3 + p40 (M)
|
Biocare Medical |
BC11+BC28 |
6 ml |
Ready-to-use |
CE/IVD |
API3067AA |
-
|
Host |
Mouse + Mouse + Rabbit |
Clone |
BC11 + BC28 + BC15 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Lung squamous cell carcinoma and lung adernocarcinoma |
Dilution |
- |
Isotype |
Mouse IgG1 + Mouse IgG1 + Rabbit IgG |
Localization |
Cell membrane + nucleus + cytoplasmic (granular) |
Desmoglein 3 + p40 (M) + Napsin A (RM)
|
Biocare Medical |
BC11 + BC28 + BC15 |
6 ml |
Ready-to-use |
CE/IVD |
API3132DSAA |
-
|
Host |
Mouse |
Clone |
DP2.15 |
Format |
Purified |
Method |
F, IF, WB |
Isotype |
Mouse IgG1 |
Immunogen |
Native bovine desmoplakin 1 and 2 |
Desmoplakin I & II
|
Zytomed Systems GmbH |
DP2.15 |
50 µg |
Purified |
RUO |
604-0060 |
-
|
Host |
Mouse |
Clone |
AC-30-10 |
Format |
Lyophilised |
Method |
IF, WB, F, P |
Isotype |
Mouse IgM |
Immunogen |
Native human DNA |
DNA
|
Zytomed Systems GmbH |
AC-30-10 |
50 µg |
Lyophilised |
RUO |
604-0095 |
-
|
Host |
Rabbit |
Clone |
SP31 |
Format |
Concentrate |
Reactivity |
BV, FG |
Method |
P |
Pretreatment |
Citrate |
Positive control |
GIST |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptides of human DOG-1 protein |
Localization |
Cytoplasm, Cell Membrane |
DOG1
|
Zytomed Systems GmbH |
SP31 |
0.1 ml |
Concentrate |
RUO |
504-3310 |
-
|
Host |
Rabbit |
Clone |
SP31 |
Format |
Concentrate |
Reactivity |
BV, FG |
Method |
P |
Pretreatment |
Citrate |
Positive control |
GIST |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptides of human DOG-1 protein |
Localization |
Cytoplasm, Cell Membrane |
DOG1
|
Zytomed Systems GmbH |
SP31 |
0.5 ml |
Concentrate |
RUO |
504-3312 |
-
|
Host |
Rabbit |
Clone |
SP31 |
Format |
Concentrate |
Reactivity |
BV, FG |
Method |
P |
Pretreatment |
Citrate |
Positive control |
GIST |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptides of human DOG-1 protein |
Localization |
Cytoplasm, Cell Membrane |
DOG1
|
Zytomed Systems GmbH |
SP31 |
1 ml |
Concentrate |
RUO |
504-3314 |
-
|
Host |
Rabbit |
Clone |
SP31 |
Format |
Concentrate |
Reactivity |
BV, FG |
Method |
P |
Pretreatment |
Citrate |
Positive control |
GIST |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptides of human DOG-1 protein |
Localization |
Cytoplasm, Cell Membrane |
DOG1
|
Zytomed Systems GmbH |
SP31 |
0.2 ml |
Concentrate |
RUO |
504-3315 |
-
|
Host |
Mouse |
Clone |
DOG1.1 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
GIST |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG |
Immunogen |
Synthetic peptide to human DOG1 |
Localization |
Cytoplasm, Cell Membrane |
DOG1
|
Diagnostic Biosystems |
DOG1.1 |
1 ml |
Concentrate |
CE/IVD |
MOB466 |
-
|
Host |
Mouse |
Clone |
DOG1.1 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
GIST |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG |
Immunogen |
Synthetic peptide to human DOG1 |
Localization |
Cytoplasm, Cell Membrane |
DOG1
|
Diagnostic Biosystems |
DOG1.1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB466-01 |
-
|
Host |
Mouse |
Clone |
DOG1.1 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
GIST |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG |
Immunogen |
Synthetic peptide to human DOG1 |
Localization |
Cytoplasm, Cell Membrane |
DOG1
|
Diagnostic Biosystems |
DOG1.1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB466-05 |
-
|
Host |
Mouse |
Clone |
DOG1.1 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
GIST |
Dilution |
- |
Isotype |
Mouse IgG |
Immunogen |
Synthetic peptide to human DOG1 |
Localization |
Cytoplasm, Cell Membrane |
DOG1
|
Diagnostic Biosystems |
DOG1.1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM170 |
-
|
Host |
Mouse |
Clone |
DOG1.1 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Breast carcinomas. |
Dilution |
1:100 |
Isotype |
IgG1 /κ |
Immunogen |
Synthetic peptides FLJ34272 specific to human gastrointestinal stromal tumor (GIST) |
Localization |
Cell membrane |
DOG1
|
Zeta Corporation |
DOG1.1 |
1 ml |
Concentrate |
CE/IVD |
Z2013ML |
-
|
Host |
Mouse |
Clone |
DOG1.1 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Breast carcinomas. |
Dilution |
- |
Isotype |
IgG1 /κ |
Immunogen |
Synthetic peptides FLJ34272 specific to human gastrointestinal stromal tumor (GIST) |
Localization |
Cell membrane |
DOG1
|
Zeta Corporation |
DOG1.1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2013MP |
-
|
Host |
Mouse |
Clone |
DOG1.1 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Breast carcinomas. |
Dilution |
1:100 |
Isotype |
IgG1 /κ |
Immunogen |
Synthetic peptides FLJ34272 specific to human gastrointestinal stromal tumor (GIST) |
Localization |
Cell membrane |
DOG1
|
Zeta Corporation |
DOG1.1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2013MS |
-
|
Host |
Mouse |
Clone |
DOG1.1 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Breast carcinomas. |
Dilution |
1:100 |
Isotype |
IgG1 /κ |
Immunogen |
Synthetic peptides FLJ34272 specific to human gastrointestinal stromal tumor (GIST) |
Localization |
Cell membrane |
DOG1
|
Zeta Corporation |
DOG1.1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2013MT |
-
|
Host |
Mouse |
Clone |
B-8 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Pancreatic adenocarcinoma. |
Dilution |
1:50 - 1:100 |
Isotype |
IgG1 /κ |
Immunogen |
Amino acid 1-552 representing full length Smad4 of human origin. |
Localization |
Nucleus |
DPC4 (SMAD4)
|
Zeta Corporation |
B-8 |
1 ml |
Concentrate |
CE/IVD |
Z2240ML |
-
|
Host |
Mouse |
Clone |
B-8 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Pancreatic adenocarcinoma. |
Dilution |
- |
Isotype |
IgG1 /κ |
Immunogen |
Amino acid 1-552 representing full length Smad4 of human origin. |
Localization |
Nucleus |
DPC4 (SMAD4)
|
Zeta Corporation |
B-8 |
7 ml |
Ready-to-use |
CE/IVD |
Z2240MP |
-
|
Host |
Mouse |
Clone |
B-8 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Pancreatic adenocarcinoma. |
Dilution |
1:50 - 1:100 |
Isotype |
IgG1 /κ |
Immunogen |
Amino acid 1-552 representing full length Smad4 of human origin. |
Localization |
Nucleus |
DPC4 (SMAD4)
|
Zeta Corporation |
B-8 |
0.5 ml |
Concentrate |
CE/IVD |
Z2240MS |
-
|
Host |
Mouse |
Clone |
B-8 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Pancreatic adenocarcinoma. |
Dilution |
1:50 - 1:100 |
Isotype |
IgG1 /κ |
Immunogen |
Amino acid 1-552 representing full length Smad4 of human origin. |
Localization |
Nucleus |
DPC4 (SMAD4)
|
Zeta Corporation |
B-8 |
0.1 ml |
Concentrate |
CE/IVD |
Z2240MT |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P, WB |
Pretreatment |
EDTA |
Positive control |
Skeletal Muscle |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide corresponding to C-terminal of human Dystrophin. |
Localization |
Cell Membrane |
Dystrophin
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
504-2662 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P, WB |
Pretreatment |
EDTA |
Positive control |
Skeletal Muscle |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide corresponding to C-terminal of human Dystrophin. |
Localization |
Cell Membrane |
Dystrophin
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
504-2664 |
-
|
Host |
Rabbit |
Clone |
EP6 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Reveal modified Citrate pH 6.0 |
Positive control |
Normal breast or breast ductal cell carcinoma |
Dilution |
1:100 - 1:200 |
Isotype |
Rabbit IgG |
Localization |
Membrane |
E-Cadherin
|
Biocare Medical |
EP6 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3012A |
-
|
Host |
Rabbit |
Clone |
EP6 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Reveal modified Citrate pH 6.0 |
Positive control |
Normal breast or breast ductal cell carcinoma |
Dilution |
1:100 - 1:200 |
Isotype |
Rabbit IgG |
Localization |
Membrane |
E-Cadherin
|
Biocare Medical |
EP6 |
1 ml |
Concentrate |
CE/IVD |
ACI3012C |
-
|
Host |
Rabbit |
Clone |
CDH1/2208R |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Normal breast or breast ductal cell carcinoma |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Localization |
Cell membrane and cytoplasm |
E-Cadherin
|
Biocare Medical |
CDH1/2208R |
0.1 ml |
Concentrate |
CE/IVD |
ACI3230A |
-
|
Host |
Rabbit |
Clone |
CDH1/2208R |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Normal breast or breast ductal cell carcinoma |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Localization |
Cytoplasm and cell membrane |
E-Cadherin
|
Biocare Medical |
CDH1/2208R |
1 ml |
Concentrate |
CE/IVD |
ACI3230C |
-
|
Host |
Rabbit |
Clone |
EP6 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Reveal modified Citrate pH 6.0 |
Positive control |
Normal breast or breast ductal cell carcinoma |
Dilution |
- |
Isotype |
Rabbit IgG |
Localization |
Membrane |
E-Cadherin
|
Biocare Medical |
EP6 |
6 ml |
Ready-to-use |
CE/IVD |
API3012AA |
-
|
Host |
Rabbit |
Clone |
CDH1/2208R |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Normal breast or breast ductal cell carcinoma |
Dilution |
- |
Isotype |
Rabbit IgG |
Localization |
Cytoplasm and cell membrane |
E-Cadherin
|
Biocare Medical |
CDH1/2208R |
6 ml |
Ready-to-use |
CE/IVD |
API3230AA |
-
|
Host |
Mouse |
Clone |
SPM471 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Breast carcinoma, colon carcinoma, appendix |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG2b kappa |
Immunogen |
Recombinant protein encoding human Cadherin-E 600-707aa |
Localization |
Cell Membrane |
E-Cadherin
|
Diagnostic Biosystems |
SPM471 |
1 ml |
Concentrate |
CE/IVD |
MOB550 |
-
|
Host |
Mouse |
Clone |
SPM471 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Breast carcinoma, colon carcinoma, appendix |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG2b kappa |
Immunogen |
Recombinant protein encoding human Cadherin-E 600-707aa |
Localization |
Cell Membrane |
E-Cadherin
|
Diagnostic Biosystems |
SPM471 |
0.1 ml |
Concentrate |
CE/IVD |
MOB550-01 |
-
|
Host |
Mouse |
Clone |
SPM471 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Breast carcinoma, colon carcinoma, appendix |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG2b kappa |
Immunogen |
Recombinant protein encoding human Cadherin-E 600-707aa |
Localization |
Cell Membrane |
E-Cadherin
|
Diagnostic Biosystems |
SPM471 |
0.5 ml |
Concentrate |
CE/IVD |
MOB550-05 |
-
|
Host |
Mouse |
Clone |
SPM471 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Breast carcinoma, colon carcinoma, appendix |
Dilution |
- |
Isotype |
Mouse IgG2b kappa |
Immunogen |
Recombinant protein encoding human Cadherin-E 600-707aa |
Localization |
Cell Membrane |
E-Cadherin
|
Diagnostic Biosystems |
SPM471 |
6 ml |
Ready-to-use |
CE/IVD |
PDM182 |
-
|
Host |
Monospecific Mouse |
Clone |
ZM63 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Skin or breast carcinoma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 /κ |
Immunogen |
Recombinant human E-Cadherin protein |
Localization |
Cell membrane |
E-Cadherin
|
Zeta Corporation |
ZM63 |
1 ml |
Concentrate |
CE/IVD |
Z2373ML |
-
|
Host |
Monospecific Mouse |
Clone |
ZM63 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Skin or breast carcinoma. |
Dilution |
- |
Isotype |
IgG1 /κ |
Immunogen |
Recombinant human E-Cadherin protein |
Localization |
Cell membrane |
E-Cadherin
|
Zeta Corporation |
ZM63 |
7 ml |
Ready-to-use |
CE/IVD |
Z2373MP |
-
|
Host |
Monospecific Mouse |
Clone |
ZM63 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Skin or breast carcinoma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 /κ |
Immunogen |
Recombinant human E-Cadherin protein |
Localization |
Cell membrane |
E-Cadherin
|
Zeta Corporation |
ZM63 |
0.5 ml |
Concentrate |
CE/IVD |
Z2373MS |
-
|
Host |
Monospecific Mouse |
Clone |
ZM63 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Skin or breast carcinoma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 /κ |
Immunogen |
Recombinant human E-Cadherin protein |
Localization |
Cell membrane |
E-Cadherin
|
Zeta Corporation |
ZM63 |
0.1 ml |
Concentrate |
CE/IVD |
Z2373MT |
-
|
Host |
Mouse |
Clone |
KH95 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil, Breast Carcinoma |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse |
Localization |
Nucleus |
E2F1 Transcription factor
|
Diagnostic Biosystems |
KH95 |
1 ml |
Concentrate |
RUO |
MOB381 |
-
|
Host |
Mouse |
Clone |
KH95 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil, Breast Carcinoma |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse |
Localization |
Nucleus |
E2F1 Transcription factor
|
Diagnostic Biosystems |
KH95 |
0.1 ml |
Concentrate |
RUO |
MOB381-01 |
-
|
Host |
Mouse |
Clone |
KH95 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil, Breast Carcinoma |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse |
Localization |
Nucleus |
E2F1 Transcription factor
|
Diagnostic Biosystems |
KH95 |
0.5 ml |
Concentrate |
RUO |
MOB381-05 |
-
|
Host |
Rabbit |
Clone |
SP84 |
Format |
Concentrate |
Method |
P, WB |
Pretreatment |
Citrate |
Positive control |
Lung squamous cell carcinoma |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
A synthetic peptide corresponding to C-terminus of human EGFR protein |
Localization |
Cell Membrane |
EGFR
|
Zytomed Systems GmbH |
SP84 |
0.5 ml |
Concentrate |
RUO |
505-3842 |
-
|
Host |
Rabbit |
Clone |
SP84 |
Format |
Concentrate |
Method |
P, WB |
Pretreatment |
Citrate |
Positive control |
Lung squamous cell carcinoma |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
A synthetic peptide corresponding to C-terminus of human EGFR protein |
Localization |
Cell Membrane |
EGFR
|
Zytomed Systems GmbH |
SP84 |
1 ml |
Concentrate |
RUO |
505-3844 |
-
|